PROVECTUS BIOPHARMACEUTICALS, INC.

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immunotherapy medicines for various diseases. The company's drug product candidates are based on rose bengal sodium (RBS), a bioactive, synthetic, small molecule that is part of the halogenated xanthenes (HXs) class of molecules. Provectus's proprietary, patented, pharmaceutical-grade RBS serves as the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. Provectus was the first entity to advance RBS into clinical trials for disease treatment and is currently the only entity to consistently produce pharmaceutical-grade RBS API with a purity of nearly 100%. RBS can be administered through various routes and may exhibit both stimulatory and inhibitory effects, targeting diseases in a multi-mechanistic way. The company's RBS drug platform and pipeline include drug product candidates and non-clinical formulations that utilize different amounts of RBS delivered via various routes of administration tailored to specific disease areas. These include clinical development programs in oncology (intratumoral administration), dermatology (topical), and ophthalmology (topical). In vivo proof-of-concept programs are underway for oncology (oral), hematology (oral), wound healing (topical), and canine cancers (intratumoral). Early discovery programs in vitro cover immune vaccine adjuvants, infectious diseases, tissue regeneration and repair, and proprietary applications. Additionally, in silico computer modeling is being conducted for amyotrophic lateral sclerosis and other disease targets. Provectus holds U.S. patents covering RBS and HX medical science, receiving one patent award from the U.S. Patent and Trademark Office (USPTO) in 2025.